2022 Pediatric Research Forum Session

Document Type


Publication Date



ALK-positive histiocytosis is a rare histiocytic proliferative disorder most often seen in infants and young children. 1,2 We describe a patient with a novel presentation of this condition characterized by a palatal mass that was responsive to treatment with first-generation ALK inhibitor, crizotinib. The unique immunophenotypic and molecular characteristics of ALK-positive histiocytosis provide an opportunity for targeted therapy with ALK inhibitors and additional research should be focused on further characterization of this condition and potential treatment options. Additionally, we support the suggestion that ALK-positive histiocytosis should be considered a distinct entity from other histiocytic proliferative disorders 1,2, such as Langerhans cell histiocytosis.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.